Search PubMed⌕ Search

Biomedical subjects

J Berlie

Publications and source records attributed to J Berlie.

46 records · Page 3Linked to original sources
PubMedDate not supplied

[Cancer mortality in France. New Aspects of the presentation and analysis of data].

In France mortality statistics are the only complete source of information on cancer. Investigation of the annual figures and the application of statistical methods to their presentation and analysis has facilitated fresh studies of geographical pathology, utilizing methods of analysis with simple and multiple correlations (analysis of correlations). Certain groupings were thus revealed, notably in the case of death from bronchial carcinoma, urinary bladder and gall bladder. Two groups of departements appeared the nearest to the national levels for deaths from cancer for all body sites.

Computers↗
PubMedDate not supplied

[The chemotherapy of advanced breast cancer. A report on the first 600 cases in a cooperative programme to carry out a systematic study (1974-1977) (author's transl)].

The authors explain the objectives and the structure of a programme evolved for the methodic study of advanced breast cancers which they have worked out and carried out in cooperation with the departments of medicine in eight French anticancer centres. They analyse the initial phases, which correspond to the three first years of work. They give the state of the results that have been obtained in 603 patients using three protocols for treatment. These consisted of the administration in interrupted doses of chemotherapy which consisted of vincristine associated for the one part with cyclophosphamide and 5-fluoro-uracil and on the other hand with doxorubicine or/and with methotrexate. From this study there emerged the value of combined therapy using doxorubicine as much because of the frequency with which results better than 50% were obtained (in a randomised trial) as by their quality, which was made clear in an important series of 240 cases. They point out the conditions required to initiate the place of such a scheme in all complex therapy which aims as much at palliation as at cure, and point out how important it is to be methodical in the application of chemotherapy in order to ensure its development as an anticancer therapy.

Antineoplastic Agents↗
PubMedDate not supplied

[Is there any bimodality of the age distribution of male mammary cancer (author's transl)?].

The authors study the pattern of the curve concerning breast cancer incidence in males as a function of age. The demonstration is made that such a curve is bimodal and, more precisely, could be satisfactorily considered as being made up of the juxtaposition of two normal distribution curves. The interval thus individualized between the mean age of both groups is remarkably steady between 17 and 20 yrs. The phenomenon is not blurred by regrouping the data and the patients population could be divided into two subgroups: one with a mean age of 147 yrs, with a standard deviation of 9 yrs, and bearing on 246 patients, the other one including 1.100 patients averaging 66.5 yrs old with a standard deviation of 9.9 yrs.

Adolescent↗
PubMedDate not supplied

[Anticancerous chemotherapy trial with duborimycin. Analysis of 151 cases].

Duborimycin is a new antimitotic agent approaching danorubicin and adriamycin in activity which has been tried on 151 patients suffering from cancer of different types, is an advanced local/regional stage and/or metastatic disease. It was administered intravenously every fortnight in a mean unit dose of 400 mg, and the duration of the treatment ranged from 2 to 52 weeks. Objective improvement was registered in 56 patients of the 135 cases in whcih the results were assessed (around 41.4% of cases). In 4 cases the regression of tumour volume was greater than 50% (one of these cases was in melanoma, the other a sarcoma) and in 2 cases regression was complete (a squamous cell carcinoma and an embryonal testicular tumour). The subjective effects were appreciable in 53 of the 115 cases which could be studied (46%) and above all in the refractory pain of bony secondaries from breast cancer (a favourable response in 78% of cases). Manifestations of intolerance/toxicity were of a minor nature on the haematologic side, that cardiologic ones relatively frequent (18% of treated cases) and occasionally serious (2 cases of asystole). Great care is therefore necessary in supervision of the treatment. However, the first results obtained by this line of approach, notably in chemo-resistant forms of tumour such as melanoma and sarcomas, utilizing the very strict criteria in one analysis encourage further study of duborimycin in cases of this sort (preferably in association and in accordance with protocols of comparative trials) so that its place in cancer chemotherapy may be more precisely defined.

Adenocarcinoma↗
PubMedDate not supplied

[Chemotherapy of soft tissues sarcomas. Summary of a decade and current trends].

The results of palliative chemotherapy applied to 123 patients with disseminated soft tissue sarcomas are reviewed with the recent literature data. With the exception of embryonal rhabdomyosarcomas of children, which are considered separately, the response of these tumors to chemotherapy is poor but not negligible. The association of several active drugs should permit substantial progress, especially in the initial stage of local treatment, when the number of disseminated cells is still reduced. A follow-up of controlled clinical studies must specify the modalities of multidisciplinary treatment in an effort to reduce regional recurrence or metastasis.

Adolescent↗